Gender:
Female
Male
|
50 (79%)
13 (21%)
|
31 (80%)
8 (20%)
|
19 (79%)
5 (21%)
|
0.976
|
Age (years) (min-max) |
42 (18-69) |
42 (18-69) |
42 (19-66) |
0.804 |
CSU |
8 (13%) |
5 (13%) |
3 (13%) |
0.970 |
Comorbid CIndU: |
18 (29%) |
9 (23%) |
9 (38%) |
0.218 |
- symptomatic dermographism, |
12 (19%) |
6 (15%) |
6 (25%) |
0.345 |
- cholinergic urticaria |
7 (11%) |
5 (13%) |
2 (8%) |
0.582 |
- heat urticaria |
1 (2%) |
0 |
1 (4%) |
0.199 |
- delayed pressure urticaria |
4 (6%) |
2 (5%) |
2 (8%) |
0.612 |
- vibratory urticaria |
1 (2%) |
0 |
1 (4%) |
0.199 |
- solar urticaria |
2 (3%) |
0 |
2 (8%) |
0.067 |
- contact urticaria |
1 (2%) |
1 (3%) |
0 |
0.429 |
- aquagenic urticaria |
0 |
0 |
0 |
- |
- 2 types or more |
13 (21%) |
8 (21%) |
5 (21%) |
0.976 |
Angioedema |
33 (52%) |
22 (56%0 |
11 (46%) |
0.414 |
Hypotensive episodes |
4 (6%) |
1 (3%) |
3 (13%) |
0.116 |
Allergic rhinitis |
20 (32%) |
10 (26%) |
10 (42%) |
0.185 |
Asthma |
14 (22%) |
8 (21%) |
6 (25%) |
0.677 |
Atopic dermatitis |
2 (3%) |
2 (5%) |
0 |
0.423 |
Autoimmune disorders |
15 (24%) |
10 (26%) |
5 (21%) |
0.663 |
Oncology |
2 (3%) |
2 (5%) |
0 |
0.260 |
Family history of ColdU |
6 (10%) |
3 (8%) |
3 (13%) |
0.528 |
H1-Antihistamines licensed doses |
50 (79%) |
31 (79%) |
19 (79%) |
0.976 |
H1-Antihistamines escalated doses |
9 (14%) |
6 (15%) |
3 (13%) |
0.751 |
Omalizumab |
2 (3%) |
2 (5%) |
0 |
0.260 |
Duration of ColdU (months) |
60 (11-360) |
24 (11-71) |
212 (60-360) |
<0.001 |
UCT |
11 (6-16) |
10 (6-13) |
13 (9-16) |
0.028 |
DLQI |
4 (0-10) |
6 (2-10) |
0 (0-4) |
0.006 |